Inhibition of mitochondrial fission protein Drp1 ameliorates skeletal myopathy in the D2-mdx model of Duchenne muscular dystrophy
American Journal of Physiology-Cell Physiology · 01.07.2025 · 329 (1) · C307-C324
DOI: 10.1152/ajpcell.01009.2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.07.2025. Verfasst von H Grace Rosen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Massachusetts Boston, Boston, Massachusetts, United States. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Dynamins, Mitochondrial Dynamics, Quinazolinones. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
The therapeutic potential of targeting mitochondrial dynamics in treating myopathy in Duchenne muscular dystrophy (DMD) remains unknown. This study is the first to target Drp1-mediated mitochondrial fission to alleviate myopathy in DMD. We reported that Mdivi-1, a pharmacological inhibitor targeting Drp1-mediated mitochondrial fission, was effective in reducing muscle damage and improving skeletal muscle strength in D2-mdx mice. These responses were associated with improved mitochondrial morphology and reduced lipid peroxidation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts, United States.
- Department of Exercise and Health Sciences, University of Massachusetts Boston, Boston, Massachusetts, United States.
- Department of Biomedical and Nutritional Sciences, University of Massachusetts Lowell, Lowell, Massachusetts, United States.
- Department of Physical Therapy and Kinesiology, University of Massachusetts Lowell, Lowell, Massachusetts, United States.
ORCID-Profile: Jared Lourie, Melissa A Linden, Yuho Kim, Kai Zou
Förderung
- NIDDK NIH HHS
- NIH HHS
- HHS | National Institutes of Health (NIH)
- HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM)
Zitieren
APA
Rosen, H. G., Berger, N. J., Hodge, S. N., Fujishiro, A., Lourie, J., Kapadia, V., Duzz, T., Linden, M. A., Jee, E., Kim, J., Kim, Y., & Zou, K. (2025). Inhibition of mitochondrial fission protein Drp1 ameliorates skeletal myopathy in the D2-mdx model of Duchenne muscular dystrophy. American Journal of Physiology-Cell Physiology, 329(1), C307-C324. https://doi.org/10.1152/ajpcell.01009.2024
Vancouver
Rosen HG, Berger NJ, Hodge SN, Fujishiro A, Lourie J, Kapadia V, et al. Inhibition of mitochondrial fission protein Drp1 ameliorates skeletal myopathy in the D2-mdx model of Duchenne muscular dystrophy. American Journal of Physiology-Cell Physiology. 2025;329(1):C307-C324. doi:10.1152/ajpcell.01009.2024
BibTeX
@article{Rosen2025,
author = {Rosen, H Grace and Berger, Nicolas J and Hodge, Shantel N and Fujishiro, Atsutaro and Lourie, Jared and Kapadia, Vrusti and Duzz, Tessa and Linden, Melissa A and Jee, Eunbin and Kim, Jonghan and Kim, Yuho and Zou, Kai},
title = {Inhibition of mitochondrial fission protein Drp1 ameliorates skeletal myopathy in the D2-mdx model of Duchenne muscular dystrophy},
journal = {American Journal of Physiology-Cell Physiology},
year = {2025},
volume = {329},
number = {1},
pages = {C307--C324},
doi = {10.1152/ajpcell.01009.2024}
}
EUVIMED